# Bio-Rad Laboratories, Inc.: overview

BIO · NYSE · CIK 12208 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/bio.md) · [Financials](/companies/bio/financials.md) · [Filings](/companies/bio/filings.md) · [Insiders](/companies/bio/insiders.md)

Latest reported revenue: [$651.0m](/filings/0000012208-26-000048.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 4, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0000012208-26-000048).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [650](/filings/0000012208-25-000077.md) | [668](/filings/0000012208-25-000007.md) | [585](/filings/0000012208-26-000035.md) | [652](/filings/0000012208-26-000048.md) | [653](/filings/0000012208-25-000077.md) | [693 d](/filings/0000012208-26-000010.md) | [592](/filings/0000012208-26-000035.md) | [651](/filings/0000012208-26-000048.md) |
| Gross margin | % | [54.8%](/filings/0000012208-25-000077.md) | [51.2%](/filings/0000012208-25-000007.md) | [52.3%](/filings/0000012208-26-000035.md) | [53.0%](/filings/0000012208-26-000048.md) | [52.6%](/filings/0000012208-25-000077.md) | [49.8% d](/filings/0000012208-26-000010.md) | [52.3%](/filings/0000012208-26-000035.md) | [53.1%](/filings/0000012208-26-000048.md) |
| Operating margin | % | [9.9%](/filings/0000012208-25-000077.md) | [8.7% d](/filings/0000012208-26-000010.md) | [4.0%](/filings/0000012208-26-000035.md) | [11.8%](/filings/0000012208-26-000048.md) | [10.0%](/filings/0000012208-25-000077.md) | [(17.2%) d](/filings/0000012208-26-000010.md) | [5.8%](/filings/0000012208-26-000035.md) | [11.2%](/filings/0000012208-26-000048.md) |
| Net margin | % | [100.5%](/filings/0000012208-25-000077.md) | [(107.2%)](/filings/0000012208-25-000007.md) | [10.9%](/filings/0000012208-26-000048.md) | [48.8%](/filings/0000012208-26-000048.md) | [(52.4%)](/filings/0000012208-25-000077.md) | [103.9% d](/filings/0000012208-26-000010.md) | [(89.0%)](/filings/0000012208-26-000048.md) | [57.1%](/filings/0000012208-26-000048.md) |
| Diluted EPS | $ per share | [23.34](/filings/0000012208-25-000077.md) | [(25.57)](/filings/0000012208-25-000007.md) | [2.29](/filings/0000012208-26-000035.md) | [11.67](/filings/0000012208-26-000048.md) | [(12.70)](/filings/0000012208-25-000077.md) | not reported | [(19.55)](/filings/0000012208-26-000035.md) | [13.85](/filings/0000012208-26-000048.md) |
| Free cash flow | $m | [123 d](/filings/0000012208-25-000077.md) | [81.3 d](/filings/0000012208-26-000010.md) | [95.5](/filings/0000012208-26-000035.md) | [70.8 d](/filings/0000012208-26-000048.md) | [89.2 d](/filings/0000012208-25-000077.md) | [119 d](/filings/0000012208-26-000010.md) | [78.1](/filings/0000012208-26-000035.md) | [66.7 d](/filings/0000012208-26-000048.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2,923](/filings/0000012208-24-000013.md) | [2,802](/filings/0000012208-25-000007.md) | [2,671](/filings/0000012208-26-000010.md) | [2,567](/filings/0000012208-26-000010.md) | [2,583](/filings/0000012208-26-000010.md) |
| Gross margin | % | [56.1%](/filings/0000012208-24-000013.md) | [55.9%](/filings/0000012208-25-000007.md) | [53.4%](/filings/0000012208-26-000010.md) | [53.7%](/filings/0000012208-26-000010.md) | [51.9%](/filings/0000012208-26-000010.md) |
| Operating margin | % | [17.1%](/filings/0000012208-24-000013.md) | [17.2%](/filings/0000012208-25-000007.md) | [12.6%](/filings/0000012208-26-000010.md) | [10.5%](/filings/0000012208-26-000010.md) | [1.8%](/filings/0000012208-26-000010.md) |
| Net margin | % | [145.6%](/filings/0000012208-24-000013.md) | [(129.5%)](/filings/0000012208-25-000007.md) | [(23.9%)](/filings/0000012208-26-000010.md) | [(71.9%)](/filings/0000012208-26-000010.md) | [29.4%](/filings/0000012208-26-000010.md) |
| Diluted EPS | $ per share | [140.83](/filings/0000012208-24-000013.md) | [(121.79)](/filings/0000012208-24-000013.md) | [(21.82)](/filings/0000012208-26-000010.md) | [(65.36)](/filings/0000012208-26-000010.md) | [27.85](/filings/0000012208-26-000010.md) |
| Free cash flow | $m | [536](/filings/0000012208-24-000013.md) | [81.6](/filings/0000012208-25-000007.md) | [218](/filings/0000012208-26-000010.md) | [290](/filings/0000012208-26-000010.md) | [375](/filings/0000012208-26-000010.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/bio/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [First Eagle Investment Management, LLC](/funds/1325447.md) | 2026-06-30 | $765.2m | 2,606,219 |  | Added +3,447 |
| [First Eagle Investment Management, LLC](/funds/1325447.md) | 2026-06-30 | $765.2m | 2,606,219 |  | Added +3,447 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $498.8m | 1,698,929 |  | Added +18,869 |
| [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $277.3m | 944,548 |  | Reduced −144,775 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $242.8m | 826,972 |  | Reduced −4,193 |
| [ARIEL INVESTMENTS, LLC](/funds/936753.md) | 2026-06-30 | $239.8m | 816,751 |  | Added +30,790 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $239.6m | 816,198 |  | Reduced −12,988 |
| [EARNEST PARTNERS LLC](/funds/1102578.md) | 2026-06-30 | $170.5m | 580,752 |  | Reduced −7,979 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $167.9m | 571,762 |  | Added +12,192 |
| [BANK OF AMERICA CORP /DE/](/funds/70858.md) | 2026-06-30 | $144.0m | 490,412 |  | Added +45,455 |

## Recent filings

[All 1,158 filings](/companies/bio/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-04 | 16:20 ET | [10-Q](/filings/0000012208-26-000048.md) | Quarterly report, period 2026-06-30 | 0000012208-26-000048 |
| 2026-08-04 | 16:16 ET | [8-K](/filings/0000012208-26-000046.md) | 2.02 Results of operations; 2.05 Exit or disposal costs; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000012208-26-000046 |
| 2026-04-30 | 16:19 ET | [10-Q](/filings/0000012208-26-000035.md) | Quarterly report, period 2026-03-31 | 0000012208-26-000035 |
| 2026-04-30 | 16:17 ET | [8-K](/filings/0000012208-26-000034.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000012208-26-000034 |
| 2026-04-24 | 16:30 ET | [8-K](/filings/0000012208-26-000024.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0000012208-26-000024 |
| 2026-03-25 | 16:17 ET | [DEF 14A](/filings/0000012208-26-000020.md) | Proxy statement, period 2026-04-21 | 0000012208-26-000020 |
| 2026-02-19 | 16:15 ET | [8-K](/filings/0000012208-26-000012.md) | 7.01 Regulation FD disclosure | 0000012208-26-000012 |
| 2026-02-13 | 21:50 ET | [10-K](/filings/0000012208-26-000010.md) | Annual report, period 2025-12-31 | 0000012208-26-000010 |
| 2026-02-12 | 16:16 ET | [8-K](/filings/0000012208-26-000007.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000012208-26-000007 |
| 2025-10-30 | 16:36 ET | [SCHEDULE 13D/A](/filings/0000940805-25-000007.md) | Ownership report, active investor, amended | 0000940805-25-000007 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0000012208-26-000010.md), filed Feb 13, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/5f9d8a78-7141-4c22-9f43-05356fcd6ddd)

## About the filer

- CIK: 12208
- Tickers: BIO, BIO-B
- Exchange: NYSE
- SIC code: 3826 Laboratory Analytical Instruments
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 16:58 ET. No prices; not investment advice.